中银创新医疗混合A

Search documents
8月20日中银创新医疗混合A净值下跌2.30%,近1个月累计上涨2.96%
Sou Hu Cai Jing· 2025-08-20 13:01
金融界2025年8月20日消息,中银创新医疗混合A(007718) 最新净值2.2431元,下跌2.30%。该基金近1个 月收益率2.96%,同类排名3737|4049;近6个月收益率77.59%,同类排名28|3916;今年来收益率 86.41%,同类排名31|3882。 中银创新医疗混合A股票持仓前十占比合计62.83%,分别为:信达生物(8.33%)、科伦博泰生 (8.15%)、恒瑞医药(8.08%)、康方生物(8.07%)、新诺威(6.13%)、百利天恒(5.99%)、百济 神州-U(5.97%)、翰森制药(4.15%)、荣昌生物(4.05%)、康诺亚-B(3.91%)。 来源:金融界 公开资料显示,中银创新医疗混合A基金成立于2019年11月13日,截至2025年6月30日,中银创新医疗 混合A规模12.66亿元,基金经理为郑宁。 简历显示:郑宁先生:中国,研究生、硕士。曾任泰康资产管理有限责任公司股票研究经理、高级股票研 究经理;中庚基金管理有限公司研究员、高级研究员(医药组组长)。2022年加入中银基金管理有限公司。 2022年7月1日担任中银创新医疗混合型证券投资基金基金经理。2022年10月 ...
中银基金郑宁:超额收益来自底部和顶部的逆向
点拾投资· 2025-07-24 09:35
Core Viewpoint - The article emphasizes the importance of long-term value investing in the innovative pharmaceutical sector, highlighting the successful strategies employed by Zheng Ning, a fund manager at Zhongyin Fund, who has achieved significant returns by investing in innovative drugs during market downturns and focusing on long-term pricing rather than short-term fluctuations [1][2][3]. Group 1: Investment Strategy - Zheng Ning's investment approach is characterized by a focus on long-term pricing, filtering out short-term noise and market fluctuations, which distinguishes him from many growth stock fund managers [3][12]. - He has demonstrated a willingness to take contrarian positions, investing heavily in innovative drugs when the market was pessimistic and shifting focus to less popular sectors as the market evolves [3][4][30]. - The performance of his funds, such as Zhongyin Hong Kong Stock Connect Pharmaceutical Mixed A, which achieved an 84.18% return over the past year, reflects the effectiveness of his strategy [2]. Group 2: Market Insights - The innovative pharmaceutical sector is experiencing a collective explosion in growth, with significant revenue increases and profitability improvements among companies in this space [2][23]. - Zheng Ning believes that the current competitive landscape in China's innovative drug market is undergoing rapid changes due to policy shifts, which could lead to substantial opportunities for well-positioned companies [21][22]. - The article notes that the success of Chinese innovative drugs in international markets is a surprising development, with companies generating substantial overseas revenue [24]. Group 3: Risk Management - Zheng Ning emphasizes the importance of being responsible for every position held in the portfolio, focusing on risk-reward ratios rather than short-term performance rankings [4][29]. - He advocates for a balanced approach to investing, suggesting that maintaining a stable life outside of work can enhance investment performance [57]. - The article highlights the need for investors to be cautious at market peaks and to recognize when to take profits, contrasting this with the opportunities available at market bottoms [36][50]. Group 4: Future Outlook - Looking ahead, Zheng Ning is optimistic about the continued growth of the innovative pharmaceutical sector but is also exploring investment opportunities in domestic demand sectors that are currently undervalued [45][46]. - He anticipates that as the market matures, the investment landscape will shift towards higher risk and lower win rates, similar to trends observed in the U.S. market [22][24]. - The article concludes with Zheng Ning's assertion that he is not solely an innovative drug fund manager but rather a broader pharmaceutical industry manager, indicating potential shifts in his investment focus as market conditions change [48][49].
7月23日中银创新医疗混合A净值下跌0.96%,近1个月累计上涨13.58%
Sou Hu Cai Jing· 2025-07-23 14:27
Group 1 - The core point of the article highlights the performance and holdings of the Zhongyin Innovation Medical Mixed A fund, which has shown significant returns over various time frames, including a 76.52% return year-to-date [1] - The fund's recent net value is reported at 2.1241 yuan, with a slight decline of 0.96% [1] - The fund's performance rankings are notable, with a 13.58% return over the past month (ranked 488 out of 4001), an 80.76% return over the past six months (ranked 25 out of 3880), and a 76.52% return year-to-date (ranked 26 out of 3861) [1] Group 2 - The top ten stock holdings of the Zhongyin Innovation Medical Mixed A fund account for a total of 62.83%, with significant positions in companies such as Innovent Biologics (8.33%), Kelun-Biotech (8.15%), and Hengrui Medicine (8.08%) [1] - The fund was established on November 13, 2019, and as of June 30, 2025, it has a total scale of 1.266 billion yuan [1] - The fund manager, Zheng Ning, has a background in stock research and has held various positions in asset management companies before joining Zhongyin Fund Management in 2022 [2]
7月10日中银创新医疗混合A净值下跌0.61%,近1个月累计下跌2.55%
Sou Hu Cai Jing· 2025-07-10 12:54
Group 1 - The core viewpoint of the news is the performance and holdings of the Zhongyin Innovation Medical Mixed A fund, which has shown a decline in recent net value but strong performance over the past six months and year-to-date [1] - As of July 10, 2025, the latest net value of Zhongyin Innovation Medical Mixed A is 1.9240 yuan, reflecting a decrease of 0.61%. The fund's return over the past month is -2.55%, ranking 3762 out of 3974 in its category. However, its six-month return is 69.25%, ranking 25 out of 3870, and its year-to-date return is 59.89%, ranking 26 out of 3868 [1] - The top ten stock holdings of Zhongyin Innovation Medical Mixed A account for a total of 70.44%, with significant positions in companies such as Kelun-Botai (9.77%), Hengrui Medicine (9.39%), and Innovent Biologics (8.54%) [1] Group 2 - Zhongyin Innovation Medical Mixed A was established on November 13, 2019, and as of March 31, 2025, it has a total scale of 2.613 billion yuan. The fund manager is Zheng Ning [1] - Zheng Ning has a background in finance and has held various positions in asset management, including roles at Taikang Asset Management and Zhonggeng Fund Management. He joined Zhongyin Fund Management in 2022 and has been managing multiple funds since then [2]
6月26日中银创新医疗混合A净值下跌2.05%,近1个月累计上涨11.87%
Sou Hu Cai Jing· 2025-06-26 12:46
Group 1 - The core point of the news is the performance of the Zhongyin Innovation Medical Mixed A fund, which has shown significant returns over various time frames, with a year-to-date return of 55.70% and a recent one-month return of 11.87% [1] - The fund's top ten stock holdings account for a total of 70.44%, with notable companies such as Kelun-Botai (9.77%), Hengrui Medicine (9.39%), and Innovent Biologics (8.54%) leading the portfolio [1] - As of March 31, 2025, the fund has a total size of 2.613 billion yuan, and it was established on November 13, 2019, with Zheng Ning as the fund manager [1] Group 2 - Zheng Ning has a strong background in the investment management industry, having previously worked as a stock research manager at Taikang Asset Management and as a senior researcher at Zhonggeng Fund Management [2] - Zheng Ning has been managing the Zhongyin Innovation Medical Mixed Fund since July 1, 2022, and has taken on additional fund management roles in the healthcare sector since then [2]
6月18日中银创新医疗混合A净值增长0.64%,今年来累计上涨57.01%
Sou Hu Cai Jing· 2025-06-18 13:57
Core Insights - The latest net value of Zhongyin Innovation Medical Mixed A Fund (007718) is 1.8893 CNY, with a growth of 0.64% [1] - The fund has shown a one-month return of 16.39%, ranking 76 out of 4640 in its category; a six-month return of 50.83%, ranking 25 out of 4486; and a year-to-date return of 57.01%, ranking 24 out of 4506 [1] Fund Holdings - The top ten stock holdings of Zhongyin Innovation Medical Mixed A Fund account for a total of 70.44%, with the largest positions being: - Kelun-Botai (9.77%) - Heng Rui Pharmaceutical (9.39%) - Innovent Biologics (8.54%) - CanSino Biologics (8.24%) - CanSino-B (6.59%) - New Horizon Health (6.27%) - BeiGene-U (6.02%) - Baillie Gifford (5.89%) - Hutchison China MediTech (5.16%) - Hansoh Pharmaceutical (4.57%) [1] Fund Management - Zhongyin Innovation Medical Mixed A Fund was established on November 13, 2019, and as of March 31, 2025, it has a total asset size of 2.613 billion CNY [1] - The fund manager is Zheng Ning, who has a background in stock research and has held positions at various asset management companies before joining Zhongyin Fund Management in 2022 [2]
6月12日中银创新医疗混合A净值增长4.23%,今年来累计上涨68.97%
Sou Hu Cai Jing· 2025-06-12 12:21
Group 1 - The core point of the article highlights the performance of the Zhongyin Innovation Medical Mixed A fund, which has shown significant growth in its net value and returns over various time frames [1] - As of June 12, 2025, the fund's latest net value is 2.0332 yuan, reflecting a growth of 4.23%. The fund has achieved a return of 29.59% over the past month, 53.60% over the past six months, and 68.97% year-to-date, ranking 77 out of 4655, 28 out of 4508, and 26 out of 4536 respectively [1] - The top ten stock holdings of the fund account for a total of 70.44%, with significant positions in companies such as Kelun-Botai (9.77%), Hengrui Medicine (9.39%), and Innovent Biologics (8.54%) [1] Group 2 - The Zhongyin Innovation Medical Mixed A fund was established on November 13, 2019, and as of March 31, 2025, it has a total asset size of 2.613 billion yuan [1] - The fund manager, Zheng Ning, has a background in asset management and has held various positions in the industry, including roles at Taikang Asset Management and Zhonggeng Fund Management [2] - Zheng Ning has been managing the Zhongyin Innovation Medical Mixed A fund since July 1, 2022, and has also taken on management roles for other funds within the Zhongyin family [2]
5月27日中银创新医疗混合A净值增长2.02%,今年来累计上涨39.18%
Sou Hu Cai Jing· 2025-05-27 12:55
Group 1 - The core viewpoint of the news is the performance and holdings of the Zhongyin Innovation Medical Mixed A fund, which has shown a recent net value increase of 2.02% and a year-to-date return of 39.18% [1] - The fund's recent performance includes a one-month return of -0.39%, a six-month return of 25.97%, and a year-to-date return ranking of 40 out of 4544 in its category [1] - The top ten stock holdings of the fund account for a total of 70.44%, with significant positions in companies such as Kelun-Botai (9.77%), Hengrui Medicine (9.39%), and Innovent Biologics (8.54%) [1] Group 2 - The Zhongyin Innovation Medical Mixed A fund was established on November 13, 2019, and as of March 31, 2025, it has a total scale of 2.613 billion yuan [1] - The fund manager, Zheng Ning, has a background in asset management and has held various positions in the industry, including roles at Taikang Asset Management and Zhonggeng Fund Management [2] - Zheng Ning has been managing the Zhongyin Innovation Medical Mixed A fund since July 1, 2022, and has also taken on management roles for other funds within the Zhongyin family [2]
5月23日中银创新医疗混合A净值下跌0.86%,近1个月累计上涨1.79%
Sou Hu Cai Jing· 2025-05-23 12:34
Group 1 - The core point of the news is the performance and holdings of the Zhongyin Innovation Medical Mixed A fund, which has shown significant returns over various time frames [1] - As of May 23, 2025, the latest net value of the fund is 1.7095 yuan, with a recent decline of 0.86% [1] - The fund's one-month return is 1.79%, ranking 1325 out of 2536 in its category; the six-month return is 31.89%, ranking 26 out of 2456; and the year-to-date return is 42.07%, ranking 14 out of 2485 [1] Group 2 - The top ten stock holdings of the Zhongyin Innovation Medical Mixed A fund account for a total of 70.44%, with the largest holdings being Kelun-Botai (9.77%), XD Hengrui Medicine (9.39%), and Innovent Biologics (8.54%) [1] - The fund was established on November 13, 2019, and as of March 31, 2025, it has a total scale of 2.613 billion yuan [1] - The fund manager, Zheng Ning, has a background in asset management and has held various positions in the industry before joining Zhongyin Fund Management in 2022 [2]
5月12日中银创新医疗混合A净值下跌4.72%,近1个月累计下跌0.88%
Sou Hu Cai Jing· 2025-05-12 12:11
Group 1 - The core point of the news is the performance and holdings of the Zhongyin Innovation Medical Mixed A fund, which has seen a recent decline in net value and varying returns over different time frames [1] - As of May 12, 2025, the latest net value of Zhongyin Innovation Medical Mixed A is 1.5689 yuan, reflecting a decrease of 4.72% [1] - The fund's performance over the past month shows a return of -0.88%, ranking 254 out of 4688 in its category; over the past three months, it has achieved a return of 30.43%, ranking 16 out of 4622; and since the beginning of the year, it has returned 30.38%, ranking 34 out of 4581 [1] Group 2 - The top ten stock holdings of Zhongyin Innovation Medical Mixed A account for a total of 70.44%, with the largest positions in Kelun-Botai (9.77%), Hengrui Medicine (9.39%), and Innovent Biologics (8.54%) [1] - The fund was established on November 13, 2019, and as of March 31, 2025, it has a total scale of 2.613 billion yuan [1] - The fund manager, Zheng Ning, has a background in asset management and has held various positions in the industry before joining Zhongyin Fund Management in 2022 [2]